Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PDE6D | O43924 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368048 | 0.96 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2368051 | 0.96 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL246625 | 0.94 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL246624 | 0.94 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1022804 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1021914 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1021915 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL11302951 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4079327 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4079332 | 0.94 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086945-B1 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LAB PRIVATE LTD (IN) | 2016-01-06 | — | — | EP | disclosed |
| EP-2024341-B1 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LAB PRIVATE LTD (IN) | 2015-12-02 | — | — | EP | disclosed |
| US-8455640-B2 | Process for statins and its pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8455640-B2 | Process for statins and its pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8404841-B2 | Process for the preparation of statins and their pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-8404841-B2 | Process for the preparation of statins and their pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | MSN LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| WO-2007125547-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | HMGCR, PCSK9, NPC1L1 | HMGCR 1/4885ALDH1A1 1715/4885CYP3A4 13/4885 |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | HMGCR, NPC1L1, PCSK9 | HMGCR 1/4885ALDH1A1 1466/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.